SHARKDREAMS
SHARKDREAMS
The most interesting thing about LIVIT wasn't the device — it was where it sat: in the gap between a Medicaid health plan, a specialty pharmacy, and a self-administering patient nobody could see. This is how that triangle works, and how LIVIT tried to close the loop.
Specialty drugs are a small share of prescriptions and a huge share of cost. The patients who take them are often older, lower-income, and managing serious chronic disease at home — and once the bottle leaves the pharmacy, the pharmacy is blind. LIVIT was built to give them eyes.
People assume specialty pharmacy is a commercial-insurance, Medicare-Part-D story. Ours wasn't. Both LIVIT clients were anchored to Medicaid managed-care organizations — the plans that carry the financial risk for low-income and dual-eligible members:
That matters because the same organization owns the pharmacy and carries the medical risk. When a Medicaid member on a $4,000-a-month specialty drug stops taking it and lands in the hospital, the plan eats that cost. So the plan-owned specialty pharmacy has a direct, dollar reason to know — early — whether the patient is actually taking the medicine. That is exactly the signal LIVIT produced.
The patient base therefore skewed Medicaid and dual-eligible — not the affluent, tech-comfortable patient a consumer health gadget would target. That single fact shaped everything that follows.
A specialty "self-administration" patient is someone managing a complex, high-cost condition — oral oncology, HIV, hepatitis C, multiple sclerosis, transplant immunosuppression, autoimmune disease — by themselves, at home, with no clinician in the room. The therapy is unforgiving: miss doses on an HIV or transplant regimen and the consequence isn't discomfort, it's resistance, rejection, or relapse.
And yet adherence is hard for ordinary human reasons: side effects, complex multi-drug schedules, cognitive load, cost anxiety, simply forgetting. The pharmacy ships a 30- or 90-day supply and then cannot see a single thing until the next refill is — or isn't — requested. By the time a late refill flags a problem, weeks of missed doses have already happened.
The home was the most important room in the care plan, and it was the one room nobody could see into.
Before connected devices, a specialty pharmacy's adherence program was built on human follow-up and inference, not measurement:
Adherence was estimated from refill timing (PDC / MPR). A patient who refills on schedule looks adherent — even if the pills sit in a drawer.
Scheduled check-in calls and counseling. Valuable, but periodic, labor-intensive, and dependent on the patient answering honestly.
Automated calls and texts to prompt the next refill — a nudge to re-order, not evidence of a dose taken.
"How's it going with the medication?" Patients under-report missed doses, for understandable reasons. The data is soft.
All of it circled the same blind spot: no ground truth on the individual dose. The pharmacy was managing the most expensive, highest-stakes therapy in healthcare with the weakest possible signal.
LIVIT was deliberately B2B. We did not try to sell a gadget to consumers. We sold the specialty pharmacy a capability: a real-time adherence signal on its own at-risk patients, delivered into a pharmacist's dashboard, priced near the cost of the hardware so the value lived in the recurring monitoring rather than the device margin.
The loop was simple to state: the LIVIT disc on the bottle weighs a real dose, the data flows through the platform's five links to the pharmacy, and the moment a patient slips, the pharmacist — not an algorithm — is put in the loop to call, counsel, or escalate. For a plan-owned specialty pharmacy carrying the risk, that early signal is worth far more than the $25 device that produces it.
See the five communication links → See the pay model →By design, LIVIT relied on the patient's smartphone as the bridge: the disc talks to a phone app over Bluetooth, and the app relays the dose data to the cloud. For a tech-comfortable patient that works cleanly. But our population skewed older, lower-income, Medicaid and dual-eligible — and a phone-based design raises real questions for that group:
The honest answer is that we never got the data back to know. The pharmacy never reported the patient-engagement statistics that would have told us whether less tech-savvy patients were actually using the app — so the adoption question stayed open.
To de-risk that open question, we sketched a dedicated home hub: a small always-on box the patient simply plugs in, that reads the LIVIT disc over Bluetooth and ships the data over its own cellular (3G) connection — no smartphone, no app, no home WiFi. We explored building it on Microsoft Azure Sphere for its chip-to-cloud security, since this would be unattended health data sitting in someone's home. It got as far as a concept and a pitch (including a Düsseldorf invite), but it was a research-build idea — no formal partnership was signed, and the hub was never completed. LIVIT remained a phone-app-based product.